ASLAN Pharmaceuticals

Aslan Pharmaceuticals’ ASLAN001 receives FDA Orphan designation

Monday, August 17, 2015

Aslan Pharmaceuticals, a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumor types, has received Orphan Drug designation for its pan-HER inhibitor ASLAN001 (varlitinib) from the FDA Office of Orphan Products Development (OOPD). The indication for the Orphan Drug designation is cholangiocarcinoma, a rare and very aggressive form of bile duct cancer that has no cure.

[Read More]

Aslan Pharmaceuticals, National Cancer Center Singapore collaborate

Wednesday, July 22, 2015

Aslan Pharmaceuticals, an oncology focused biotechnology company, and National Cancer Center Singapore (NCCS) have signed a Memorandum of Understanding (MOU) that will further enhance the study of novel therapeutic agents for the treatment of gastric cancer, hepatocellular carcinoma (liver) and cholangiocarcinoma (bile duct), three common forms of gastrointestinal (GI) cancers that are particularly prevalent in Asia. 

[Read More]

ASLAN Pharmaceuticals, CSL ink agreement for asthma

Wednesday, May 14, 2014

ASLAN Pharmaceuticals, a specialty pharmaceutical company developing novel medicines for global markets, with offices in Singapore and Taiwan, has announced a global license agreement to develop CSL anti-IL13 receptor monoclonal antibody, CSL334, currently in preclinical development for the treatment of asthma. CSL Limited is a global biopharmaceutical company headquartered in Melbourne, Australia that develops, manufactures and markets biotherapies to prevent and treat serious human diseases.

[Read More]